Archimed

About

ARCHIMED - Impacting Healthcare About Us Fund Support Return Our Companies left About Us Our Companies Sustainability Impact Fund Our Investment Strategy Our Investors Our Funds Support Our Value Creation Approach Our Team and Network Return Return to Investors Return to People Return to Society right News JOIN OUR TEAM Investor Portal Contact Add impact to your LinkedIn Keep up with the latest updates, insights, and opportunities driving meaningful change in the healthcare industries Follow us See our latest news ARCHIMED Life Science Tools & Services acquires IRAB, a leading independent radiopharmaceuticals platform The ARCHIMED Life Science Tools Services team of global private equity healthcare specialist ARCHIMED announces the acquisition of 100% of Institut de Radiofarmàcia Aplicada de Barcelona, S.L. (IRAB), a Barcelona-based specialist in the development, production and commercialization of Positron Emission Tomography (PET) radiopharmaceuticals for clinical diagnosis, clinical trials and biomedical research. PET is a medical imaging technique that allows clinicians to see how organs and tissues are functioning inside the body. Unlike CT (computed tomography) scans or MRI (magnetic resonance imaging), which capture morphological changes, PET detects physiological and biochemical alterations, enabling earlier diagnosis before structural abnormalities become visible. IRAB manufactures radiotracers, specialized radioactive drugs used for PET imaging for the diagnosis of

Key Contact

Geographic Focus